Man smiling behind laptop)

CSL Behring Newsroom

Recent News Releases

CSL Behring, Leader in Rare Diseases, Showcases Innovations in Neuromuscular Medicine (NMM) at the 2018 American Academy of Neurology Annual Meeting
20 Apr 2018 News Release

- CSL Behring will host an industry therapeutic update highlighting findings from the PATH trial, the largest clinical trial in CIDP, and present key poster presentations featuring advances in the field of NMM

- Exhibition booth (#846) will feature interactive simulation exercises allowing attendees to experience typical CIDP symptoms

- CSL Behring is now the only company to offer a portfolio of biologics to address the unique needs of CIDP patients in the US – Hizentra®, the first and only subcutaneous immunoglobulin option for CIDP patients and Privigen®, the No.1 intravenous immunoglobulin used in hospitals is now available for CIDP patients

Life-Saving Medicines Donated for Patients in the Developing World
12 Apr 2018 News Release

CSL Behring Marks World Hemophilia Day by Shipping IUs of its Bleeding Disorders Medicines to the World Federation of Hemophilia

Forbes Magazine Names CSL Limited Among Top 50 Employers in the World
20 Mar 2018 News Release

Global biotech leader rated at no. 42 for patient focus, innovation and sustainable growth

FDA Approves Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) for the Treatment of Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
16 Mar 2018 News Release

First and only subcutaneous immunoglobulin (SCIg) approved for the treatment of CIDP based on the largest controlled clinical study in CIDP

CSL Behring Receives Patient Impact Award for Subcutaneous Prophylactic Treatment to Prevent Hereditary Angioedema Attacks
15 Mar 2018 News Release

Life Sciences Pennsylvania recognized CSL Behring’s commitment to patients for its novel subcutaneous C1 esterase inhibitor, HAEGARDA®, to prevent swelling caused by the rare genetic disorder

Want to know more about how we are sharing stories of biotech's promise?

Read Vita

CSL Behring Media Contacts

Natalie de Vane

Corporate Inquiries
Phone: +1 610-878-4468

Greg Healy

Product Inquiries
(Bleeding disorders and Warfarin reversal)
Phone: +1 610-878-4841

Christopher Florentz

Corporate Inquiries
Phone: +1 610-878-4316

Jennifer Purdue

Product Inquiries
(Immune disorders, Alpha-1, HAE)
Phone: +1 610-878-4802

CSL Behring Production Sites

Sandra Ruckstuhl

Bern, Switzerland
Phone: +41 31-344-1124

Maureen E. Powell

Kankakee, Illinois, USA
Phone: +1 815-935-3120

Stephanie Fuchs

Marburg, Germany
Phone: +49 6421 39-5972

Christina Hickie

Broadmeadows, Victoria, Australia
Phone: +61 429 609 762

Past News Releases by Year

News Archives 2016 pdf
News Archives 2015 pdf
News Archives 2014  pdf
News Archives 2013  pdf
News Archives 2012  pdf

Get our latest news in your inbox

mail@example.com
First name
Last name
Country

Thanks!

You have now been added
to the CSL Behring news list